Turning Point Therapeutics, Inc. engages in designing and developing therapies that target genetic drivers of cancer. Its lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC)
Market Cap | 3.772 Billion | Shares Outstanding | 49.62 Million | Avg 30-day Volume | 962.413 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.87 |
Price to Revenue | 3710.4566 | Debt to Equity | 0.0 | EBITDA | -335.554 Million |
Price to Book Value | 4.7163 | Operating Margin | -34185.813500000004 | Enterprise Value | 2.922 Billion |
Current Ratio | 16.828 | EPS Growth | -1.153 | Quick Ratio | 16.557 |
1 Yr BETA | 1.0812 | 52-week High/Low | 82.2 / 23.77 | Profit Margin | -33959.0278 |
Operating Cash Flow Growth | -189.2363 | Altman Z-Score | 43.1826 | Free Cash Flow to Firm | -226.25 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2022-08-17 | 1 | |
|
0 | 2022-08-17 | 1 | |
|
0 | 2022-08-17 | 1 | |
COUNTOURIOTIS ATHENA PRESIDENT & CEO |
|
0 | 2022-08-17 | 2 |
|
0 | 2022-08-17 | 1 | |
|
0 | 2022-08-17 | 1 | |
HIRMAND MOHAMMAD EVP AND CHIEF MEDICAL OFFICER |
|
0 | 2022-08-17 | 2 |
TOMBESI PAOLO EVP & CHIEF FINANCIAL OFFICER |
|
0 | 2022-08-17 | 3 |
|
0 | 2022-08-17 | 1 | |
SUN BRIAN SVP & GENERAL COUNSEL |
|
0 | 2022-08-17 | 3 |
SABUS STEVE M SVP & CHIEF COMMERCIAL OFFICER |
|
0 | 2022-08-17 | 3 |
NORTH ANNETTE EVP & GENERAL COUNSEL |
|
86,579 | 2022-02-09 | 1 |
REICH SIEGFRIED EVP & CHIEF SCIENTIFIC OFFICER |
|
65,848 | 2022-02-09 | 1 |
PARTRIDGE ANDREW JOHN EVP & CHIEF COMMERCIAL OFFICER |
|
96,961 | 2022-02-09 | 1 |
VAN HOOSE KYRI K. PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2021-05-14 | 0 |
BAKER BRIAN LEE SVP OF FINANCE AND ADMIN. |
|
32,443 | 2021-03-22 | 0 |
LARSON YI EVP & CHIEF FINANCIAL OFFICER |
|
7,321 | 2021-02-08 | 0 |
|
0 | 2020-06-15 | 0 | |
|
0 | 2020-06-15 | 0 | |
|
0 | 2020-06-15 | 0 | |
|
1,841,681 | 2020-06-09 | 0 | |
|
2,253,660 | 2020-05-21 | 0 | |
|
No longer subject to file | 2019-08-12 | 0 | |
|
2,027,550 | 2019-04-22 | 0 | |
|
1,742,550 | 2019-04-22 | 0 | |
ALTA CALIFORNIA PARTNERS II LP ALTA CALIFORNIA MANAGEMENT PARTNERS II LLC ALTA EMBARCADERO PARTNERS II LLC ALTA CALIFORNIA PARTNERS II, L.P. -- NEW POOL ALTA CALIFORNIA MANAGEMENT PARTNERS II, LLC -- NEW POOL |
|
2,229,706 | 2006-10-03 | 0 |
ALTA BIOPHARMA MANAGEMENT III LLC ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG ALTA BIOPHARMA PARTNERS III LP |
|
2,229,706 | 2006-10-03 | 0 |
|
2,642,583 | 2006-10-03 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 22:15:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 21:45:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 21:15:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 20:45:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 20:15:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 19:45:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 19:15:05 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 18:45:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 18:15:05 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 17:45:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 17:15:03 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 16:45:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 16:15:03 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 15:45:03 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 15:15:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 14:45:04 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 14:15:03 UTC | -0.8111 | 3.1311 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 13:45:03 UTC | -3.786 | 6.106 | 100000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 13:15:04 UTC | -3.786 | 6.106 | 150000 |
TURNING POINT THERAPEUTICS I TPTX | 2022-08-17 12:45:04 UTC | -3.786 | 6.106 | 150000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Index Plus All-Cap Fund | TPTX | -1.0 shares, $-44.66 | 2020-03-31 | N-PORT |
Trust for Professional Managers- Convergence Long/Short Equity Fund | TPTX | -372.0 shares, $-14158.32 | 2021-11-30 | N-PORT |